Navigation Links
Prostate Cancer Treatment Centre Receives Funding for Clinical Trials

Clinical Trial Aimed to Supplement Current Research Findings on the

Treatment of Localized Prostate Cancer

TORONTO, Nov. 14 /PRNewswire/ -- A Canadian study on High Intensity Focused Ultrasound therapy with the Sonablate(R) 500 - a Health Canada approved treatment for localized prostate cancer - is underway at Can-Am HIFU. Through funding from AstraZeneca Canada Inc, Can-Am HIFU, a prostate cancer treatment centre, will conduct an REB/Health Canada approved clinical trial. The objective of the study is to supplement current research findings on safety and efficacy of HIFU therapy in the treatment of localized prostate cancer. The trial will measure both the biochemical (PSA) cure rates and the Biopsy-proven cure rates at one year.

"AstraZeneca is committed to promoting excellence in Canadian health science research and to supporting the growth of Canada's scientific community," says Marc Zarenda, Scientific Director - Oncology at AstraZeneca Canada Inc. "We are excited to put our support behind this clinical trial."

The nation-wide study will involve a select number of men and will be led by Can-Am HIFU urologists Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD. The study will play an integral role in building Canadian data on HIFU therapy.

Currently, the data on HIFU are from studies conducted in other countries," said Dr. Barkin, Chief of Staff, Humber River Regional Hospital and Director of Can-Am HIFU. "As more patients are considering HIFU as an alternative treatment option for prostate cancer, we recognize the need to build Canadian data on HIFU therapy."

HIFU has been used in several countries for a number of years to treat men with localized prostate cancer and benign prostatic hyperplasia. The therapy uses ultrasound energy to heat and destroy specifically targeted areas of the prostate. HIFU was approved for use in the treatment of prostate cancer in Canada in June 2005. Can-Am HIFU urologists have been treating patients from Canada and abroad on an out-patient basis since March 2006. Currently the Sonablate(R) 500 is undergoing clinical trials in the United States and has not been approved for U.S. marketing by the FDA.

For more information on the study please contact Can-Am HIFU at 1 -877- 787-5906. For more information on HIFU with the Sonablate(R) 500, please visit

About Can-Am HIFU

Can-Am HIFU is a Canadian entity of USHIFU, LLC. The clinic, located in Toronto, was established in March 2006 and solely treats localized prostate cancer using HIFU with the Sonablate(R) 500. Can-Am HIFU physicians include Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD.


USHIFU, LLC is a development company headquartered in Charlotte, NC. USHIFU is the exclusive distributor of the Sonablate(R) 500 in North, South and Central America, the island nations of the Caribbean and South Africa. The company holds a minority ownership position in Focus Surgery Inc. of Indianapolis, the world leader in the development of HIFU products and the manufacturer of the Sonablate(R) 500 in conjunction with Misonix, Inc (MSON).

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):